VOYAGER THERAPEUTICS INC (VYGR) Stock Income Statement
NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 80.00M | 250.01M | 40.90M | 37.40M | 171.10M | |||
| Operating Expenses | 160.49M | 127.99M | 91.70M | 111.00M | 143.70M | |||
| Research and Development | 124.57M | 92.17M | 60.80M | 73.80M | 108.80M | |||
| Selling, General, and Administrative Expenses | 35.92M | 35.82M | 31.00M | 37.20M | 35.00M | |||
| Operating Income | -80.49M | 122.01M | -50.80M | -73.60M | 27.40M | |||
| Interest Income/Expense | 18.33M | 11.72M | 1.80M | -400.00K | 1.70M | |||
| Other Income/Expense | 622.00K | 3.00K | 2.70M | 2.80M | 7.70M | |||
| Non Recurring Items | -2.80M | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -64.34M | 133.74M | -46.40M | -71.20M | 36.70M | |||
| Income Tax | 665.00K | 1.41M | 0.00 | N/A | 0.00 | |||
| Net Income | -65.00M | 132.33M | -46.40M | -71.20M | 36.70M | |||
| EBITDA | -75.76M | 126.45M | -44.61M | -68.43M | 31.22M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.13 | 2.97 | -1.21 | -1.89 | 0.98 | |||
| Non GAAP EPS | -1.13 | 3.09 | -1.22 | -1.90 | 0.95 | |||
| Statistics | ||||||||
| Profit Margin | -81.25% | 52.93% | -113.45% | -190.37% | 21.45% | |||
| Operating Profit Margin | -100.61% | 48.80% | -124.21% | -196.79% | 16.01% | |||
All data in USD